Sugi Predict

Sugi Predict / Compounds / SCHEMBL726302

SCHEMBL726302

SCHEMBL726302

CC(=O)N[C@@H](CCCCN)C(N)=O

nearest known ligand 0.56

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ SIRT6 Q8N6T7 1/20 0.56
▸ SIRT1 Q96EB6 1/20 0.56
▸ SIRT5 Q9NXA8 2/20 0.47
▸ CA1 P00915 2/20 0.46
▸ CA2 P00918 2/20 0.46
▸ TLR2 O60603 2/20 0.45
▸ ALB P02768 1/20 0.45
▸ FOLH1 Q04609 1/20 0.45
▸ HPGDS O60760 1/20 0.45
▸ CHRM2 P08172 1/20 0.44
▸ CHRM4 P08173 1/20 0.44
▸ CHRM1 P11229 1/20 0.44
▸ PAOX Q6QHF9 2/20 0.42
▸ ITGB3 P05106 4/20 0.42
▸ ITGA2B P08514 4/20 0.42
▸ GNPAT O15228 1/20 0.40
▸ GSR P00390 1/20 0.39
▸ FURIN P09958 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11896083 1.00 SIRT6 (0.56) SIRT6SIRT1SIRT5CA1CA2
Hydrochloric Acid SCHEMBL7347980 0.98 SIRT6 (0.55) SIRT6SIRT1SIRT5CA1CA2
SCHEMBL24520157 0.94 SIRT6 (0.50) SIRT6SIRT1SIRT5CA1CA2
SCHEMBL20435058 0.90 SIRT6 (0.58) SIRT6SIRT1SIRT5CA1CA2
SCHEMBL20435077 0.90 SIRT6 (0.58) SIRT6SIRT1SIRT5CA1CA2
SCHEMBL12749404 0.90 SIRT6 (0.58) SIRT6SIRT1SIRT5CA1CA2
SCHEMBL20952057 0.89 SIRT6 (0.51) SIRT6SIRT1SIRT5CA1CA2
SCHEMBL20952056 0.89 SIRT6 (0.51) SIRT6SIRT1SIRT5CA1CA2
SCHEMBL20951744 0.86 FURIN (0.52) SIRT6SIRT1SIRT5CA1CA2
SCHEMBL20951745 0.86 FURIN (0.52) SIRT6SIRT1SIRT5CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9445992-B2 Mucosal delivery compositions comprising a peptide complexed with a crown compound and/or a counter ion ARISGEN SA (CH) 2016-09-20 — — US claimed
CN-102770152-B The mucosal delivery of peptides 阿瑞斯根股份有限公司 2016-07-06 — — CN claimed
WO-2013004716-A1 PEPTIDE BEADS UNIVERSITÄT BASEL (CH) 2013-01-10 — — WO claimed
US-20120302502-A1 MUCOSAL DELIVERY COMPOSITIONS COMPRISING A PEPTIDE COMPLEXED WITH A CROWN COMPOUND AND/OR A COUNTER ION ARISGEN SA (CH) 2012-11-29 — — US claimed
EP-2504019-A2 MUCOSAL DELIVERY COMPOSITION COMPRISING A PEPTIDE COMPLEXED WITH A CROWN COMPOUND AND/OR A COUNTER ION ArisGen SA (CH) 2012-10-03 — — EP claimed
WO-2011064316-A2 MUCOSAL DELIVERY OF PEPTIDES BOTTI PAOLO (CH) 2011-06-03 — — WO claimed
CN-1038103-A The glutaramide diuretic agents of cycloalkyl substituted and its preparation method PFIZER (US) 1989-12-20 — — CN claimed
US-20240360089-A1 Metabolically Stable HDAC Inhibitors with Trifluoromethylpyruvamide as Metal-Binding Group THE UNIVERSITY OF TOLEDO (US) 2024-10-31 — — US disclosed
US-20240116985-A1 STAPLED PEPTIDES AND METHODS THEREOF PARABILIS MEDICINES, INC. 2024-04-11 — — US disclosed
CN-115335524-A RNA for complement inhibition 阿佩利斯制药有限公司 2022-11-11 — — CN disclosed
US-10973923-B2 Site specific homogeneous with KSP inhibitors BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2021-04-13 — — US disclosed
US-20190262463-A1 SITE SPECIFIC HOMOGENEOUS WITH KSP INHIBITORS BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2019-08-29 — — US disclosed
EP-2609426-B1 FLUORESCENCE LABELING REAGENTS AND USES THEREOF TEXAS A & M UNIV SYS (US) 2018-12-19 — — EP disclosed
WO-2012027717-A2 FLOURESCENCE LABELING REAGENTS AND USES THEREOF THE TEXAS A&M UNIVERSITY SYSTEM (US) 2012-03-01 — — WO disclosed
WO-2011079315-A1 TYROSINE BIOCONJUGATION THROUGH AQUEOUS ENE-LIKE REACTIONS THE SCRIPPS RESEARCH INSTITUTE (US) 2011-06-30 — — WO disclosed
WO-2011064316-A2 MUCOSAL DELIVERY OF PEPTIDES BOTTI PAOLO (CH) 2011-06-03 — — WO disclosed
US-20080032322-A1 Method for incorporation of two oxygen atoms into digested peptides using peptidases UNIVERSITY OF NORTH DAKOTA (US) 2008-02-07 — — US disclosed
EP-0327365-B1 Improvements in or relating to modified haptens useful as imaging and therapeutic agents HYBRITECH INC (US) 1994-06-15 — — EP disclosed
WO-1993002652-A2 MODIFIED HAPTENS USEFUL AS IMAGING AND THERAPEUTIC AGENTS HYBRITECH INCORPORATED (US) 1993-02-18 — — WO disclosed
EP-0327365-A2 Improvements in or relating to modified haptens useful as imaging and therapeutic agents HYBRITECH INCORPORATED (US) 1989-08-09 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240360089-A1 Metabolically Stable HDAC Inhibitors with Trifluoromethylpyruvamide as Metal-Binding Group HDAC1, HDAC3, HDAC2 SIRT6 56/4885SIRT1 16/4885SIRT5 72/4885
US-20120302502-A1 MUCOSAL DELIVERY COMPOSITIONS COMPRISING A PEPTIDE COMPLEXED WITH A CROWN COMPOUND AND/OR A COUNTER ION VIP, CFTR, IAPP SIRT6 3744/4885SIRT1 4096/4885SIRT5 4663/4885
US-20240116985-A1 STAPLED PEPTIDES AND METHODS THEREOF CTNNB1, APC, CTNNA1 SIRT6 3309/4885SIRT1 3454/4885SIRT5 3966/4885
US-20190262463-A1 SITE SPECIFIC HOMOGENEOUS WITH KSP INHIBITORS KIF5B, KIF15, KIF2C SIRT6 2866/4885SIRT1 3442/4885SIRT5 3254/4885
US-10973923-B2 Site specific homogeneous with KSP inhibitors KIF5B, KIF15, KIF2C SIRT6 2866/4885SIRT1 3442/4885SIRT5 3254/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback